Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1992 2
1996 1
1998 1
1999 1
2001 1
2002 2
2009 1
2010 3
2011 3
2016 2
2017 3
2020 2
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
Management of borderline ovarian tumours.
Gershenson DM. Gershenson DM. Best Pract Res Clin Obstet Gynaecol. 2017 May;41:49-59. doi: 10.1016/j.bpobgyn.2016.09.012. Epub 2016 Oct 3. Best Pract Res Clin Obstet Gynaecol. 2017. PMID: 27780698 Review.
Approximately 3000 American women are diagnosed with borderline ovarian tumours annually. Borderline tumours are similar to other types of adnexal masses. ...However, because the accuracy of frozen-section examination is lower than optimal, caution is …
Approximately 3000 American women are diagnosed with borderline ovarian tumours annually. Borderline tumours are …
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Chen LM, Cristea M, DeRosa M, Eisenhauer EL, Gershenson DM, Gray HJ, Grisham R, Hakam A, Jain A, Karam A, Konecny GE, Leath CA, Liu J, Mahdi H, Martin L, Matei D, McHale M, McLean K, Miller DS, O'Malley DM, Percac-Lima S, Ratner E, Remmenga SW, Vargas R, Werner TL, Zsiros E, Burns JL, Engh AM. Armstrong DK, et al. J Natl Compr Canc Netw. 2021 Feb 2;19(2):191-226. doi: 10.6004/jnccn.2021.0007. J Natl Compr Canc Netw. 2021. PMID: 33545690
These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar manner. Most of the recommendations are based on data from patients with the most common subtypeshigh-grade serous and grade 2/3 endo …
These NCCN Guidelines discuss cancers originating in the ovary, fallopian tube, or peritoneum, as these are all managed in a similar …
Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria.
Hauptmann S, Friedrich K, Redline R, Avril S. Hauptmann S, et al. Virchows Arch. 2017 Feb;470(2):125-142. doi: 10.1007/s00428-016-2040-8. Epub 2016 Dec 27. Virchows Arch. 2017. PMID: 28025670 Free PMC article. Review.
Borderline ovarian tumors (BOT) are uncommon but not rare epithelial ovarian neoplasms, intermediate between benign and malignant categories. ...Serous borderline tumors (SBT) share molecular and genetic alterations with low-grade sero …
Borderline ovarian tumors (BOT) are uncommon but not rare epithelial ovarian neoplasms, intermediate between benign and …
Management of Borderline ovarian tumors (BOT): results of a retrospective, single center study in Switzerland.
Kipp B, Vidal A, Lenick D, Christmann-Schmid C. Kipp B, et al. J Ovarian Res. 2023 Jan 23;16(1):20. doi: 10.1186/s13048-023-01107-3. J Ovarian Res. 2023. PMID: 36691070 Free PMC article.
BACKGROUND: Borderline tumors are malignant epithelial ovarian tumors with a very low incidence. ...The aim of this study was to present and analyze data of women with borderline ovarian tumor (BOT) regarding clinical features, histological char …
BACKGROUND: Borderline tumors are malignant epithelial ovarian tumors with a very low incidence. ...The aim of this stu …
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art".
Tropé C, Davidson B, Paulsen T, Abeler VM, Kaern J. Tropé C, et al. Eur J Gynaecol Oncol. 2009;30(5):471-82. Eur J Gynaecol Oncol. 2009. PMID: 19899396 Review.
The 5-year survival for women with Stage-I borderline tumours (BOT) is favourable, about 95-97%, but the 10-year survival is only between 70 and 95%, caused by late recurrence. ...In which group of patients is fertility-sparing surgery advisable and, do patients wit …
The 5-year survival for women with Stage-I borderline tumours (BOT) is favourable, about 95-97%, but the 10-year survival is o …
Fertility-sparing treatment for serous borderline ovarian tumors with extra-ovarian invasive implants: Analysis from the MITO14 study database.
Falcone F, Malzoni M, Carnelli M, Cormio G, De Iaco P, Di Donato V, Ferrandina G, Raspagliesi F, Sorio R, Losito NS, Greggi S. Falcone F, et al. Gynecol Oncol. 2022 May;165(2):302-308. doi: 10.1016/j.ygyno.2022.02.018. Epub 2022 Feb 26. Gynecol Oncol. 2022. PMID: 35232587
OBJECTIVE: Only 10-15% of serous borderline ovarian tumors (BOTs) with extra-ovarian disease have invasive implants, and conservative treatments have been rarely reported. ...Only patients undergoing fertility-sparing surgery (FSS) were included, while patien …
OBJECTIVE: Only 10-15% of serous borderline ovarian tumors (BOTs) with extra-ovarian disease have invasive implants, an …
Interventions for the treatment of borderline ovarian tumours.
Faluyi O, Mackean M, Gourley C, Bryant A, Dickinson HO. Faluyi O, et al. Cochrane Database Syst Rev. 2010 Sep 8;2010(9):CD007696. doi: 10.1002/14651858.CD007696.pub2. Cochrane Database Syst Rev. 2010. PMID: 20824864 Free PMC article. Review.
BACKGROUND: The safety of conservative surgery and the benefit of additional interventions after surgery for borderline ovarian tumours are unknown. OBJECTIVES: To evaluate the benefits and harm of different treatment modalities offered for borderline ovarian …
BACKGROUND: The safety of conservative surgery and the benefit of additional interventions after surgery for borderline ovarian tu …
SOX6 Expression Is Sensitive for Peritoneal Epithelioid Malignant Mesothelioma, But Not Specific in the Differential Diagnosis With Tubo-ovarian Serous Neoplasia.
Chapel DB, Hirsch MS. Chapel DB, et al. Am J Surg Pathol. 2022 Feb 1;46(2):213-219. doi: 10.1097/PAS.0000000000001792. Am J Surg Pathol. 2022. PMID: 34411029
SOX6 immunohistochemistry was performed on 43 peritoneal epithelioid MM, 7 peritoneal biphasic MM, 5 well-differentiated papillary mesotheliomas, 5 serous borderline tumors, 29 low-grade serous carcinomas (LGSCs), 20 high-grade serous …
SOX6 immunohistochemistry was performed on 43 peritoneal epithelioid MM, 7 peritoneal biphasic MM, 5 well-differentiated papil …
Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas.
Shappell HW, Riopel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Shappell HW, et al. Am J Surg Pathol. 2002 Dec;26(12):1529-41. doi: 10.1097/00000478-200212000-00001. Am J Surg Pathol. 2002. PMID: 12459620 Review.
Ovarian endocervical-type (mullerian) mucinous tumors and tumors composed of a mixture of endocervical-type mucinous, serous, endometrioid, squamous, and indifferent cells with abundant eosinophilic cytoplasm reported to date have been primarily limited to …
Ovarian endocervical-type (mullerian) mucinous tumors and tumors composed of a mixture of endocervical-type mucinous, serou …
Borderline ovarian tumors: French guidelines from the CNGOF. Part 2. Surgical management, follow-up, hormone replacement therapy, fertility management and preservation.
Bourdel N, Huchon C, Abdel Wahab C, Azaïs H, Bendifallah S, Bolze PA, Brun JL, Canlorbe G, Chauvet P, Chereau E, Courbiere B, De La Motte Rouge T, Devouassoux-Shisheboran M, Eymerit-Morin C, Fauvet R, Gauroy E, Gauthier T, Grynberg M, Koskas M, Larouzee E, Lecointre L, Levêque J, Margueritte F, D'argent Mathieu E, Nyangoh-Timoh K, Ouldamer L, Raad J, Raimond E, Ramanah R, Rolland L, Rousset P, Rousset-Jablonski C, Thomassin-Naggara I, Uzan C, Zilliox M, Daraï E. Bourdel N, et al. J Gynecol Obstet Hum Reprod. 2021 Jan;50(1):101966. doi: 10.1016/j.jogoh.2020.101966. Epub 2020 Nov 2. J Gynecol Obstet Hum Reprod. 2021. PMID: 33144266
In the Early Stages (ES) of Borderline Ovarian Tumor (BOT), if surgery without risk of tumor rupture is possible, then laparoscopy with protected extraction is recommended over laparotomy (Grade C). ...For serous or mucinous ES BOTs, routine hysterecto …
In the Early Stages (ES) of Borderline Ovarian Tumor (BOT), if surgery without risk of tumor rupture is possible, then …
23 results